However, inherent or acquired resistance to anti-VEGF therapy is frequently observed in tumors (6), thus demonstrating the requirement for targeting additional angiogenesis pathways to fully exploit the strategies of anti-angiogenic cancer therapy. Here, VEGFA is linked to cancer.